Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

U.S. court blocks sale of Indivior rival generic

Indivior Plc’s shares jumped more than 33 percent after a U.S. court blocked a rival from selling a cheaper copycat of the British drugmaker’s bestselling opioid addiction treatment.

Read More »

Trump told Pfizer CEO price hikes hurt his drug plan: source

U.S. President Donald Trump called Pfizer Chief Executive Ian Read to say the company’s July 1 price hikes had complicated the administration’s drug pricing plans, prompting the company to defer its planned increases, according to a source familiar with the matter.

Read More »

Pfizer Raises Prices Of Forty-Plus Drugs Per Report

The Wall Street Journal reported that Pfizer increased the list prices for more than 40 of the pharma giant’s prescribed medications.

Read More »

U.S. District Court rules in favor of Lilly’s Alimta patent

A U.S. District Court ruled in favor of Eli Lilly’s patent on its Alimta vitamin regimen and prevented Hospira and Dr. Reddy’s Laboratories from launching generics until the patent expires.

Read More »

Consumer Group Pressures FDA to Pull Takeda’s Gout Drug from Market

Consumer advocacy group Public Citizen petitioned the FDA to pull Takeda’s gout treatment Uloric (febuxostat) off the market.

Read More »

More evidence of NSAID risk in early pregnancy

Using non-steroidal anti-inflammatory drugs (NSAIDs) around the time of conception significantly increases the risk of miscarriage in the first eight weeks of pregnancy, a study suggests.

Read More »

Soaring costs, loss of benefits top Americans’ healthcare worries: Reuters/Ipsos poll

Americans listed healthcare as the most important problem facing the country, according to Reuters/Ipsos polling.

Read More »

Payer Access Special Feature: Straining the system

Current health systems built to evaluate and pay for traditional drugs are going to struggle with gene and other unusual therapies – but manufacturers can take steps before launch to define how manufacturers assess and value these new products.

Read More »

Annual Report 2018: State of the Bio Industry

This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.

Read More »

DTC Special Feature: Which color is it?

A recent study of DTC advertising appearing in the Journal of General Internal Medicine concluded that few broadcast ads are compliant with FDA’s guidelines. The reality, though, might not be so cut and dried.

Read More »

U.S. drug prices hit by insurer tactic against copay assistance: analysis

A recently adopted tactic by U.S. health plans to limit the financial assistance drugmakers provide directly to consumers for prescription medicines is taking a toll on drug prices, according to a new analysis.

Read More »

J&J’s Stelara Improves Crohn’s In Two-Year Study

The Janssen Pharmaceutical Companies, part of Johnson & Johnson, presented two-year data from its IM-UNITI trial of Stelara (ustekinumab) in Crohn’s disease.

Read More »

Trump assails high drug prices, avoids direct hit on industry

U.S. President Donald Trump blasted drugmakers and healthcare “middlemen” for making prescription medicines unaffordable for Americans, but healthcare stocks rose as his administration avoided aggressive direct measures to cut prices.

Read More »

In Europe, Mylan’s rivals try to plug EpiPen shortages

European makers of emergency allergy treatments are stepping up production of alternative life-saving adrenaline shots to try to fill intermittent shortages of Mylan’s market-leading EpiPen injection.

Read More »

Regeneron/Sanofi to cut price of heart drug

Regeneron Pharmaceuticals and Sanofi will cut the net price of their expensive cholesterol drug for Express Scripts customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said.

Read More »

China to cut import value-added tax on cancer drugs from May 1, 2018

China will cut the import value-added tax on cancer drugs to 3 percent from May 1, the Finance Ministry said.

Read More »

As cancer drug prices climb, value not keeping pace

The cost of new anti-cancer drugs increased more than five-fold from 2006 to 2015, but a new analysis suggests that cancer patients and insurers may be getting less for their money.

Read More »

Report Links Nuplazid to High Number of Deaths

Shares of Acadia Pharmaceuticals were down following a CNN report that raises concerns over a number of deaths and adverse events linked to the company’s Parkinson’s disease drug Nuplazid.

Read More »

Roche shares drop after deaths of patients taking Hemlibra

Roche’s shares dropped after the Swiss drugmaker told U.S.-based hemophilia advocacy groups that five patients treated with its medicine Hemlibra had died, while maintaining that the therapy was not the cause of the deaths.

Read More »

Tokyo court rejects Shire claim against Roche hemophilia drug

A Tokyo court ruled that Shire’s claim against Swiss drugmaker Roche’s new Hemlibra hemophilia medicine should be dismissed, Roche’s Japanese subsidiary Chugai said.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom